OpenURL Connection Search

Select item for more details and to access through your institution.

Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
Published in:
2018
By:
- Zhe-Yu Hu;
- Huawu Xiao;
- Mengjia Xiao;
- Yu Tang;
- Jian Sun;
- Ze-Ming Xie;
- Quchang Ouyang;
- Hu, Zhe-Yu;
- Xiao, Huawu;
- Xiao, Mengjia;
- Tang, Yu;
- Sun, Jian;
- Xie, Ze-Ming;
- Ouyang, Quchang
Publication type:
journal article
Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers.
Published in:
Frontiers in Genetics, 2020, v. 11, p. N.PAG, doi. 10.3389/fgene.2020.00829
By:
- Hu, Zhe-Yu;
- Liu, Liping;
- Xie, Ning;
- Lu, Jun;
- Liu, Zhentian;
- Tang, Yu;
- Wang, Yikai;
- Yang, Jianbo;
- Ouyang, Quchang
Publication type:
Article
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Published in:
Breast Cancer Research & Treatment, 2023, v. 197, n. 3, p. 489, doi. 10.1007/s10549-022-06785-z
By:
- Xu, Binghe;
- Sun, Tao;
- Shi, Yanxia;
- Cui, Jiuwei;
- Yin, Yongmei;
- Ouyang, Quchang;
- Liu, Qiang;
- Zhang, Qingyuan;
- Chen, Yiding;
- Wang, Shouman;
- Wang, Xiaojia;
- Tong, Zhongsheng;
- Zhong, Yahua;
- Wang, Jiayu;
- Yan, Min;
- Yan, Xi;
- Wang, Chuan;
- Feng, Jifeng;
- Wang, Xiuli;
- Hu, Gang
Publication type:
Article
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study.
Published in:
Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241286775
By:
- Zhang, Qingyuan;
- Shen, Kunwei;
- Song, Chuan-gui;
- Ouyang, Quchang;
- Liu, Zhenzhen;
- Liu, Qiang;
- Feng, Jifeng;
- Chiu, Joanne W. Y.;
- Tang, Jinhai;
- Jiang, Zefei;
- Tseng, Ling-Ming;
- Wang, Xiaojia;
- Yang, Liu;
- Qian, Chenxi;
- Shao, Zhimin
Publication type:
Article
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221122715
By:
- Yan, Min;
- Yuan, Peng;
- Ouyang, Quchang;
- Cheng, Ying;
- Han, Guohui;
- Wang, Dewei;
- Ran, Li;
- Sun, Tao;
- Zhao, Da;
- Bai, Yuju;
- Yang, Shun'e;
- Wang, Xiaojia;
- Wu, Rong;
- Zeng, Xiaohua;
- Yao, Herui;
- Ji, Xuening;
- Jiang, Jun;
- Hu, Xiaohua;
- Lin, Haifeng;
- Zheng, Liping
Publication type:
Article
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
Published in:
Investigational New Drugs, 2020, v. 38, n. 2, p. 507, doi. 10.1007/s10637-020-00903-8
By:
- Cao, Jun;
- Ouyang, Quchang;
- Wang, Shusen;
- Ragaz, Joseph;
- Wang, Xiaojia;
- Teng, Yuee;
- Wang, Biyun;
- Wang, Zhonghua;
- Zhang, Jian;
- Wang, Leiping;
- Wu, Jiong;
- Shao, Zhimin;
- Hu, Xichun
Publication type:
Article
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Published in:
Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45160-y
By:
- Li, Qiao;
- Liu, Jiaxuan;
- Zhang, Qingyuan;
- Ouyang, Quchang;
- Zhang, Yang;
- Liu, Qiang;
- Sun, Tao;
- Ye, Feng;
- Zhang, Baochun;
- Xia, Summer;
- Zhang, Bangyong;
- Xu, Binghe
Publication type:
Article
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211022890
By:
- Li, Yi;
- Li, Wei;
- Gong, Chengcheng;
- Zheng, Yabin;
- Ouyang, Quchang;
- Xie, Ning;
- Qu, Qing;
- Ge, Rui;
- Wang, Biyun
Publication type:
Article
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211022890
By:
- Li, Yi;
- Li, Wei;
- Gong, Chengcheng;
- Zheng, Yabin;
- Ouyang, Quchang;
- Xie, Ning;
- Qu, Qing;
- Ge, Rui;
- Wang, Biyun
Publication type:
Article
FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients.
Published in:
Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920915305
By:
- Xie, Ning;
- Tian, Can;
- Wu, Hui;
- Yang, Xiaohong;
- liu, Liping;
- Li, Jing;
- Xiao, Huawu;
- Gao, Jianxiang;
- Lu, Jun;
- Hu, Xuming;
- Cao, Min;
- Shui, Zhengrong;
- Tang, Yu;
- Wang, Xiao;
- Yang, Jianbo;
- Hu, Zhe-Yu;
- Ouyang, Quchang
Publication type:
Article
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
Published in:
BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12665-0
By:
- Hu, Zhe-Yu;
- Liu, Binliang;
- Xie, Ning;
- Yang, Xiaohong;
- Liu, Liping;
- Xiao, Huawu;
- Li, Jing;
- Wu, Hui;
- Gao, Jianxiang;
- Lu, Jun;
- Hu, Xuming;
- Cao, Min;
- Shui, Zhengrong;
- Tian, Can;
- Ouyang, Quchang
Publication type:
Article
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
Published in:
NPJ Breast Cancer, 2020, v. 6, n. 1, p. N.PAG, doi. 10.1038/s41523-020-00201-9
By:
- Yi, Zongbi;
- Rong, Guohua;
- Guan, Yanfang;
- Li, Jin;
- Chang, Lianpeng;
- Li, Hui;
- Liu, Binliang;
- Wang, Wenna;
- Guan, Xiuwen;
- Ouyang, Quchang;
- Li, Lixi;
- Zhai, Jingtong;
- Li, Chunxiao;
- Li, Lifeng;
- Xia, Xuefeng;
- Yang, Ling;
- Qian, Haili;
- Yi, Xin;
- Xu, Binghe;
- Ma, Fei
Publication type:
Article
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Published in:
BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02999-0
By:
- Cao, Jun;
- Teng, Yuee;
- Li, Huiping;
- Zhang, Lili;
- Ouyang, Quchang;
- Xie, Weimin;
- Pan, Yueyin;
- Song, Zhenchuan;
- Ling, Xiaoling;
- Wu, Xiaohong;
- Xu, Jingwei;
- Li, Li;
- Ren, Liping;
- Wang, Hong;
- Zhou, Dongxian;
- Luo, Jing;
- Hu, Xichun
Publication type:
Article
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
Published in:
BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02943-2
By:
- Hu, Zhe-Yu;
- Yan, Min;
- Xiong, Huihua;
- Ran, Li;
- Zhong, Jincai;
- Luo, Ting;
- Sun, Tao;
- Xie, Ning;
- Liu, Liping;
- Yang, Xiaohong;
- Xiao, Huawu;
- Li, Jing;
- Liu, Binliang;
- Ouyang, Quchang
Publication type:
Article
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Published in:
BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02527-6
By:
- Zhang, Qingyuan;
- Shao, Bin;
- Tong, Zhongsheng;
- Ouyang, Quchang;
- Wang, Yuting;
- Xu, Guoying;
- Li, Shaorong;
- Li, Huiping
Publication type:
Article
HS‐10352 in hormone receptor‐positive, HER2‐negative advanced breast cancer: A phase 1 dose‐escalation trial.
Published in:
Cancer Medicine, 2023, v. 12, n. 24, p. 21849, doi. 10.1002/cam4.6755
By:
- Ouyang, Quchang;
- Wang, Ying;
- Zhang, Jian;
- Wu, Qiong;
- Wei, Hongying;
- Li, Chuan;
- Qian, Xiaoling;
- Hu, Xichun
Publication type:
Article
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients.
Published in:
Cancer Medicine, 2022, v. 11, n. 14, p. 2767, doi. 10.1002/cam4.4652
By:
- Liu, Binliang;
- Yi, Zongbi;
- Guan, Yanfang;
- Ouyang, Quchang;
- Li, Chunxiao;
- Guan, Xiuwen;
- Lv, Dan;
- Li, Lixi;
- Zhai, Jingtong;
- Qian, Haili;
- Xu, Binghe;
- Ma, Fei;
- Zeng, Yixin
Publication type:
Article
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study.
Published in:
Cancer Medicine, 2021, v. 10, n. 19, p. 6744, doi. 10.1002/cam4.4215
By:
- Guo, Fengzhu;
- Yi, Zongbi;
- Wang, Wenna;
- Han, Yiqun;
- Yu, Pei;
- Zhang, Su;
- Ouyang, Quchang;
- Yan, Min;
- Wang, Xiaojia;
- Hu, Xichun;
- Jiang, Zefei;
- Huang, Tao;
- Tong, Zhongsheng;
- Wang, Shusen;
- Yin, Yongmei;
- Li, Hui;
- Yang, Runxiang;
- Yang, Huawei;
- Teng, Yuee;
- Sun, Tao
Publication type:
Article
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Published in:
Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-63033-4
By:
- Im, Seock-Ah;
- Xu, Binghe;
- Li, Wei;
- Robson, Mark;
- Ouyang, Quchang;
- Yeh, Dah-Cherng;
- Iwata, Hiroji;
- Park, Yeon Hee;
- Sohn, Joo Hyuk;
- Tseng, Ling-Ming;
- Goessl, Carsten;
- Wu, Wenting;
- Masuda, Norikazu
Publication type:
Article
Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China.
Published in:
Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.599604
By:
- Wu, Yun;
- Han, Yiqun;
- Yu, Pei;
- Ouyang, Quchang;
- Yan, Min;
- Wang, Xiaojia;
- Hu, Xichun;
- Jiang, Zefei;
- Huang, Tao;
- Tong, Zhongsheng;
- Wang, Shusen;
- Yin, Yongmei;
- Li, Hui;
- Yang, Runxiang;
- Yang, Huawei;
- Teng, Yuee;
- Sun, Tao;
- Cai, Li;
- Li, Hongyuan;
- Chen, Xi
Publication type:
Article
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
Published in:
International Journal of Cancer, 2023, v. 153, n. 10, p. 1809, doi. 10.1002/ijc.34676
By:
- Li, Yiqun;
- Tong, Zhongsheng;
- Wu, Xinhong;
- Ouyang, Quchang;
- Cai, Li;
- Li, Wei;
- Yu, Zhiyong;
- Han, Zhengxiang;
- Wang, Xiaojia;
- Li, Man;
- Wang, Haibo;
- Li, Li;
- Yang, Jin;
- Niu, Zhaofeng;
- Wang, Qitang;
- Xu, Binghe
Publication type:
Article
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
Published in:
2021
By:
- Chen, Shanshan;
- Han, Yiqun;
- Ouyang, Quchang;
- Lu, Jianguo;
- Zhang, Qingyuan;
- Yang, Shun'e;
- Wang, Jingfen;
- Huang, Haixin;
- Liu, Hong;
- Shao, Zhimin;
- Li, Hui;
- Chen, Zhendong;
- Sun, Sanyuan;
- Geng, Cuizhi;
- Lu, Junguo;
- Sun, Jianwei;
- Wang, Jiayu;
- Xu, Binghe
Publication type:
journal article
In Vivo Detection of CTC and CTC Plakoglobin Status Helps Predict Prognosis in Patients with Metastatic Breast Cancer.
Published in:
Pathology & Oncology Research, 2020, v. 26, n. 4, p. 2435, doi. 10.1007/s12253-020-00847-7
By:
- Xie, Ning;
- Hu, Zheyu;
- Tian, Can;
- Xiao, Huawu;
- Liu, Liping;
- Yang, Xiaohong;
- Li, Jing;
- Wu, Hui;
- Lu, Jun;
- Gao, Jianxiang;
- Hu, Xuming;
- Cao, Min;
- Shui, Zhengrong;
- Ouyang, Quchang
Publication type:
Article
HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report.
Published in:
2016
By:
- QUCHANG OUYANG;
- CAN TIAN;
- JIANXIANG GAO;
- JIN HUANG;
- HUA FU;
- JINSONG HE;
- JIANBO YANG
Publication type:
Case Study
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Published in:
2016
By:
- Ayong Cao;
- Jin Zhang;
- Xiaoan Liu;
- Weizhu Wu;
- Yinhua Liu;
- Zhimin Fan;
- Anqin Zhang;
- Tianning Zhou;
- Peifen Fu;
- Shu Wang;
- Quchang Ouyang;
- Jinhai Tang;
- Hongchuan Jiang;
- Xiaohua Zhang;
- Da Pang;
- Jianjun He;
- Linxiang Shi;
- Xianming Wang;
- Yuan Sheng;
- Dahua Mao
Publication type:
journal article
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Published in:
Signal Transduction & Targeted Therapy, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41392-023-01672-5
By:
- Han, Yiqun;
- Wang, Jiayu;
- Sun, Tao;
- Ouyang, Quchang;
- Li, Jianwen;
- Yuan, Jie;
- Xu, Binghe
Publication type:
Article
Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Published in:
Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1075830
By:
- Yu Tang;
- Jing Li;
- Binliang Liu;
- Jialu Ran;
- Zhe-Yu Hu;
- Quchang Ouyang
Publication type:
Article
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
Published in:
Targeted Oncology, 2021, v. 16, n. 5, p. 591, doi. 10.1007/s11523-021-00823-4
By:
- Wang, Jiani;
- Zhang, Qingyuan;
- Li, Qiao;
- Mu, Yuxin;
- Jing, Jing;
- Li, Huiping;
- Li, Wei;
- Wang, Jingfen;
- Yu, Guohua;
- Wang, Xian;
- Ouyang, Quchang;
- Hao, Jing;
- Lu, Liang;
- Zhou, Li;
- Guan, Jin;
- Li, Qing;
- Xu, Binghe
Publication type:
Article
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy.
Published in:
Oncologist, 2021, v. 26, n. 5, p. e742, doi. 10.1002/onco.13614
By:
- Xu, Fei;
- Zheng, Qiufan;
- Xia, Wen;
- Ouyang, Quchang;
- Pang, Danmei;
- Yuan, Zhongyu;
- Shi, Yanxia;
- Peng, Roujun;
- Lu, Qianyi;
- Wang, Shusen
Publication type:
Article
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Published in:
Oncologist, 2017, v. 22, n. 11, p. 1333, doi. 10.1634/theoncologist.2017-0088
By:
- Li, Jianbin;
- Wang, Shusen;
- Wang, Yongsheng;
- Wang, Xiaojia;
- Wang, Haibo;
- Feng, Jifeng;
- Zhang, Qingyuan;
- Sun, Tao;
- Ouyang, Quchang;
- Yin, Yongmei;
- Liu, Yinhua;
- Geng, Cuizhi;
- Yan, Min;
- Jiang, Zefei
Publication type:
Article
Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.829693
By:
- Chen, Zhanhong;
- Ouyang, Quchang;
- Wang, Yongsheng;
- Wang, Junsheng;
- Wang, Haixue;
- Wu, Xiaohong;
- Zhang, Peili;
- Huang, Jian;
- Zheng, Yabing;
- Cao, Wenming;
- Shao, Xiying;
- Xie, Ning;
- Tian, Can;
- Liang, Hao;
- Wang, Cailing;
- Zhang, Ying;
- Ren, Dianquan;
- Wang, Xiaojia
Publication type:
Article
Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53 -Aberrant Triple-Negative Breast Cancer.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.804466
By:
- Hu, Zhe-Yu;
- Zheng, Chanjuan;
- Yang, Jianbo;
- Ding, Siyu;
- Tian, Can;
- Xie, Ning;
- Xue, Lian;
- Wu, Muyao;
- Fu, Shujun;
- Rao, Zhouzhou;
- Price, Matthew A.;
- McCarthy, James B.;
- Ouyang, Quchang;
- Lin, Jizhen;
- Deng, Xiyun
Publication type:
Article
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
Published in:
2020
By:
- Xu, Binghe;
- Hu, Xichun;
- Feng, Jifeng;
- Geng, Cuizhi;
- Jin, Feng;
- Li, Hongyuan;
- Li, Man;
- Li, Qing;
- Liao, Ning;
- Liu, Donggeng;
- Liu, Jian;
- Liu, Qiang;
- Lu, Jinsong;
- Liu, Zhenzhen;
- Ma, Fei;
- Ouyang, Quchang;
- Pan, Yueyin;
- Shen, Kunwei;
- Sun, Tao;
- Teng, Yuee
Publication type:
journal article
Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Published in:
2019
By:
- Liu, Jingyu;
- Li, Jing;
- Wang, Hui;
- Wang, Yikai;
- He, Qiongzhi;
- Xia, Xuefeng;
- Hu, Zhe-Yu;
- Ouyang, Quchang
Publication type:
journal article

Found: 34